<DOC>
	<DOCNO>NCT00697801</DOCNO>
	<brief_summary>The objective study evaluate efficacy , tolerability pharmacokinetics 2 dos MAP0010 ( Unit Dose Budesonide ) asthmatic children/adolescents .</brief_summary>
	<brief_title>Study MAP0010 Asthmatic Children Adolescents</brief_title>
	<detailed_description />
	<criteria>Male female asthmatic children/adolescents 1 18 year age FEV1 great equal 50 % predict normal ( obtainable ) Stable symptomatic Diagnosis asthma ( per NIH criterion ) least 3 month screen OR document exacerbation worsen asthma symptom suggestive asthma include nocturnal asthma , within 6 month screen OR document SAB use least symptom relief 4 day run total symptom score great equal 1 OR great equal 1 night disturbed due asthma symptom previous month . Any significant childhood illness . Participated investigational clinical trial within 30 day prior screen . Use corticosteroid within 2 week screen . Use oral corticosteroid within 30 day screen prolonged use oral corticosteroid within 12 week screen . Use inhaled long act bronchodilator . Presumptive documented history upper low respiratory infection within 2 week screen . Any history acute severe asthma attack require ICU admission ventilatory support . History suggestive ( diagnosis ) concomitant lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>